Becton, Dickinson and Company sits at an unusual crossroads this week — the stock rallied 14% in a month, the Street is busily lifting targets post-earnings, and the CEO just sold $8 million of shares into the strength.
The insider angle is the week's sharpest signal. Chairman and CEO Thomas Polen sold a combined 43,278 shares on August 13 at $185, pocketing roughly $8 million across two transactions. That followed a $2.5 million sale on June 1. The 90-day net across all insiders runs to about $12.1 million in net selling, with no offsetting purchases visible in the data. Divisional presidents also trimmed in the same window. The sales alone don't define the thesis — executives routinely sell into rallies — but the size and timing, right at the top of a 14% run, makes it the data point worth sitting with.
The Street, meanwhile, has been moving in the opposite direction. Analyst activity since the August 6 earnings print has been uniformly constructive on price targets, even where ratings stayed put. Citi raised its target to $204 maintaining Buy; RBC went from $175 to $180, then again to $190 within a week; Piper Sandler lifted from $161 to $175; Wells Fargo moved from $161 to $170. The consensus mean price target sits at $194, roughly 7% above the current $180.77 close. The notable split is in the ratings themselves — the majority of movers are holding at Neutral, Equal-Weight, or Sector Perform, upgrading the number but not the conviction. Citi and Barclays remain the clearest bulls with Buy and Overweight respectively. Valuation has re-rated alongside the rally: the price-to-earnings multiple has expanded by nearly 1.9 points over the past 30 days to about 14x, and EV/EBITDA has drifted up roughly 0.09 turns to 12.1x. That's not stretched by sector standards, but it's higher than where the Street was willing to underwrite the name three months ago.
Positioning in the lending market tells a quiet story — and that's the point. Short interest has been falling fast, dropping nearly 10% on the week to 3.3% of free float, its lowest reading since mid-July. Borrow costs remain negligible at 0.48%, and availability is running at 821% — meaning shares to lend dwarf current short demand by a factor of eight. There is no squeeze pressure here, no aggressive bearish conviction. The short score at 41 sits in the middle of the range, drifting lower over the past week from a recent high near 42. Options are equally calm. The put/call ratio at 0.44 is actually slightly below its 20-day average, sitting 1.2 standard deviations toward the bullish side — options traders are not hedging into anything, and the read is mild complacency rather than defensive positioning.
Institutional flows add one more data point worth noting. Invesco added over 6 million shares as of July 31 — a meaningful build — while BlackRock and State Street each added over a million. First Eagle added roughly 2.2 million. The large passive and active owners are growing positions into the same rally the CEO is selling into, which is a contrast worth flagging even if neither side is definitively "right."
Earnings are next due November 5. The last print on August 6 produced a 3.6% single-day gain and a 6.6% five-day gain — BDX rewarded holders who held through the event. Peers have been more mixed this week: BAX fell over 6% on the week and STE dropped 2.5%, while MDT gained 1.6%, leaving BDX's flat week looking relatively resilient in the group. The setup into November hinges on whether the planned Biosciences and Diagnostics separation produces clear milestones — that's where the bull and bear cases diverge most sharply, and what the next set of analyst moves will likely pivot on.
See the live data behind this article on ORTEX.
Open BDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
